Royalty Pharma: SCH plans $10.2M share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Royalty Pharma plc reports that SCH Investment Partners LLC plans to sell 150,000 Class A ordinary shares, with an aggregate market value of $10,176,000 and an approximate sale date of November 17, 2026. SCH Investment Partners LLC is listed with an Officer relationship to Royalty Pharma. The shares were acquired from the issuer in a private transaction on May 13, 2024. The planned sale is connected to a selling plan dated March 20, 2026, intended to comply with Rule 10b5-1(c).
Key Figures
Key Terms
Rule 10b5-1(c) regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What prior RPRX sales did SCH Investment Partners report?
AI-generated analysis. How Rhea-AI works. Not financial advice.